Literature DB >> 22135061

Advanced-practice pharmacists: practice characteristics and reimbursement of pharmacists certified for collaborative clinical practice in New Mexico and North Carolina.

Matthew Murawski, Kristin R Villa, Ernest J Dole, Timothy J Ives, Dale Tinker, Vincent J Colucci, Jeffrey Perdiew.   

Abstract

PURPOSE The results of a survey assessing the practice settings, clinical activities, and reimbursement experiences of pharmacists with advanced-practice designations are reported. METHODS A questionnaire was sent to all certified Pharmacist Clinicians in New Mexico and all Clinical Pharmacist Practitioners in North Carolina (a total of 189 pharmacists at the time of the survey in late 2008) to elicit information on practice settings, billing and reimbursement methods, collaborative drug therapy management (CDTM) protocols, and other issues. RESULTS Of the 189 targeted pharmacists, 64 (34%) responded to the survey. On average, the reported interval from pharmacist licensure to certification as an advanced practitioner was 11 years. The majority of survey participants were practicing in community or institutional settings, most often hospital clinics or physician offices. About two thirds of the respondents indicated that their employer handled the billing of their services using standard evaluation and management codes, with estimated total monthly billings averaging $6500. At the time of the survey, about 80% of the respondents were engaged in a CDTM protocol. The survey results suggest that pharmacists with advanced-practice designations are perceived favorably by patients and physicians and their services are in high demand, but more than one third of respondents indicated a need to justify their advanced-practice positions to administrators. CONCLUSION Pharmacists with advanced-practice designations are providing clinical services in various settings under collaborative practice arrangements that include prescribing privileges. Despite growing patient and physician acceptance, reimbursement challenges continue to be a barrier to wider use of CDTM programs.

Entities:  

Mesh:

Year:  2011        PMID: 22135061     DOI: 10.2146/ajhp110351

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  7 in total

1.  We Are Educating Pharmacists, Not "PharmDs".

Authors:  Cynthia J Boyle
Journal:  Am J Pharm Educ       Date:  2020-09       Impact factor: 2.047

Review 2.  Barriers to a full scope of pharmacy practice in primary care: A systematic review of pharmacists' access to laboratory testing.

Authors:  Jacqueline Donovan; Ross T Tsuyuki; Yazid N Al Hamarneh; Beata Bajorek
Journal:  Can Pharm J (Ott)       Date:  2019-08-06

3.  Collaborative drug therapy management: case studies of three community-based models of care.

Authors:  Margie E Snyder; Tara R Earl; Siobhan Gilchrist; Michael Greenberg; Holly Heisler; Michelle Revels; Dyann Matson-Koffman
Journal:  Prev Chronic Dis       Date:  2015-03-26       Impact factor: 2.830

4.  Advanced Practice Pharmacists: a retrospective evaluation of the efficacy and cost of ClinicaL Pharmacist PractitionErs managing ambulatory Medicare patients in North Carolina (APPLE-NC).

Authors:  Michèle M Kislan; Adam T Bernstein; Loretta R Fearrington; Timothy J Ives
Journal:  BMC Health Serv Res       Date:  2016-10-21       Impact factor: 2.655

5.  Creating a Pharmacotherapy Collaborative Practice Network to Manage Medications for Children and Youth: A Population Health Perspective.

Authors:  Richard H Parrish II; Danielle Casher; Johannes van den Anker; Sandra Benavides
Journal:  Children (Basel)       Date:  2019-04-09

6.  Positive Impact of a Pilot Pharmacist-Run Diabetes Pharmacotherapy Clinic in Solid-Organ Transplant Recipients.

Authors:  David M Newland; Angelina R Edwards; Reed C Hall; Pamela R Maxwell
Journal:  Diabetes Spectr       Date:  2018-05

7.  Pharmacists in Federally Qualified Health Centers: Models of Care to Improve Chronic Disease.

Authors:  Jennifer L Rodis; Traci R Capesius; Julie T Rainey; Magdi H Awad; Carrie Hornbeck Fox
Journal:  Prev Chronic Dis       Date:  2019-11-21       Impact factor: 2.830

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.